Next Article in Journal
Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
Next Article in Special Issue
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
Previous Article in Journal
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?
Previous Article in Special Issue
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
 
 
Review

Article Versions Notes

Cancers 2022, 14(3), 771; https://doi.org/10.3390/cancers14030771
Action Date Notes Link
article xml file uploaded 2 February 2022 12:06 CET Original file -
article xml uploaded. 2 February 2022 12:06 CET Update https://www.mdpi.com/2072-6694/14/3/771/xml
article pdf uploaded. 2 February 2022 12:06 CET Version of Record https://www.mdpi.com/2072-6694/14/3/771/pdf
article html file updated 2 February 2022 12:08 CET Original file -
article html file updated 31 July 2022 09:33 CEST Update https://www.mdpi.com/2072-6694/14/3/771/html
Back to TopTop